摘要
血管内皮生长因子通过与相应的受体结合刺激血管内皮细胞增殖和迁移,促进新生血管的生成。表皮生长因子受体的过表达甚至突变与机体多种常见肿瘤的发生和转移有着密切的关系。目前化学疗法治疗非小细胞肺癌已经成为常规的治疗方法,如今急需要另外的方法突破化疗的瓶颈。因此以VEGF和EGFR为靶点,通过现代分子生物学和遗传学等技术方法在基因及细胞分子水平对其表达、活性及其效应等多个环节进行有效抑制而达到治疗肿瘤的目的,是近年来抗肿瘤治疗新的方法和手段之一。本文就抗VEGF及抗EGFR靶向治疗方面的研究进展做一综述。
Chemotherapy has reached a therapeutic plateau in the treatment of non-small cell lung cancer （NSCLC）, and effective, better-tolerated treatment strategies are needed. An improved understanding of the molecular processes underlying tumor biology has led to the development of therapies that target these processes. Intracellular signaling pathways related to the VEGF and EGFR both play a central role in tumorigenesis as well as tumor growth, and are therefore rational targets for anti-cancer drug development. Various agents that target these pathways are in clinical development. Some of these have already changed treatment practice in NSCLC. We will identify how these agents are improving outcomes in the treatment of NSCLC.
出处
《临床医学工程》
2011年第2期312-314,共3页
Clinical Medicine & Engineering
基金
广西壮族自治区卫生厅立项课题(编号:Z2010290)
